MCMarta H. G. Costa

Marta H. G. Costa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marta H. G. Costa has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Frederico Castelo Ferreira

    Department of Bioengineering and Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

    4 shared publications
  • Claudia Lobato da Silva

    Department of Bioengineering, IBB-Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal

    3 shared publications
  • Margarida Serra

    BET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal

    3 shared publications
  • Ana Meliciano

    BET-Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras 2781-901, Portugal; Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, Oeiras 2780-157, Portugal

    2 shared publications
  • Beatriz Painho

    Instituto de Tecnologia Química e Biológica António Xavier Universidade Nova de Lisboa Oeiras Portugal

    2 shared publications
  • Beatriz Pelacho

    Department of Regenerative Medicine, Center for Applied Medical Research University of Navarra Pamplona Spain

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Bridging process diversity in cell therapies toward standardization of manufacturing workflows

    by Marta H.G. Costa, Manuel J.T. Carrondo, Paula M. Alves, Margarida Serra


  • Open Access

    Bottom-up ice growth geometry attenuates shear stress and improves the cryopreservation of hematopoietic stem cells under low DMSO concentrations

    by Rafaela Ouro Neves, Pedro Sena Rego, Marta Costa, Andreia Duarte, Claudia Lobato da Silva, Frederico Ferreira, Vitor Geraldes, Miguel Rodrigues

    Studies on cell cryopreservation have been limited by the complexity of the freezing process and challenges on controlling ice formation, managing cooling rates, and optimizing cryoprotectant concentrations. This study objective is to evaluate the impact of bottom-up and conventional radial freezing on the viability of mammalian cells, using mouse hybridoma cells and human umbilical cord blood (hUCB) derived mononuclear cells (MNCs) as cell models. The study combines experimental assays, including cell viability assays and flow cytometry characterization, with Computational Fluid Dynamic (CFD) simulations. A bottom-up freezing geometry sustained high cell viability, even at dimethyl sulfoxide (DMSO) concentrations below 5% v/v, while using conventional radial freezing led to lower cell viability below such DMSO concentrations threshold. Note that such observation is relevant for cell-based clinical applications. CFD simulations for conventional radial freezing, elucidated that the ice formed at the top of the vial is of high porosity for freezing under 10% v/v DMSO, but of low porosity for lower DMSO concentrations. The simulations reveal that later conditions can result in an increase in the shear stress, up to an order of magnitude, on cells. Overall, this study provides a rational for 10% v/v DMSO to be the optimum reported concentration for conventional freezing methods, as a result of poor control ice growth direction and higher mechanical stresses at lower DMSO concentrations. Experimental results show that bottom-up freezing, using only 2.5% v/v DMSO, allow to reach cell viabilities so high as the ones obtained for 10% v/v DMSO conventional radial freezing protocols. Importantly, the results support cell cryopreservation strategies, such as bottom-up freezing, that by controlling heat transfer direction allow using lower DMSO concentrations.

  • A roadmap towards manufacturing extracellular vesicles for cardiac repair

    by Ana F. Louro, Ana Meliciano, Paula M. Alves, Marta H.G. Costa, Margarida Serra


  • Cover Image, Volume 120, Number 9, September 2023

    by Marta H. G. Costa, Margarida S. Costa, Beatriz Painho, Carolina D. Sousa, Inês Carrondo, Enrique Oltra, Beatriz Pelacho, Felipe Prosper, Inês A. Isidro, Paula Alves, et al.

  • Open Access

    Enhanced bioprocess control to advance the manufacture of mesenchymal stromal cell‐derived extracellular vesicles in stirred‐tank bioreactors

    by Marta H. G. Costa, Margarida S. Costa, Beatriz Painho, Carolina D. Sousa, Inês Carrondo, Enrique Oltra, Beatriz Pelacho, Felipe Prosper, Inês A. Isidro, Paula Alves, et al.

    Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) act as signaling mediators of cellular responses. However, despite representing a promising alternative to cell‐based therapies, clinical translation of EVs is currently limited by their lack of scalability and standardized bioprocessing. Herein, we integrated scalable downstream processing protocols with standardized expansion of large numbers of viable cells in stirred‐tank bioreactors to improve EV production. Higher EV yields were linked to EV isolation by tangential flow filtration followed by size exclusion chromatography, rendering 5 times higher number of EVs comparatively to density gradient ultracentrifugation protocols. Additionally, when compared to static culture, EV manufacture in bioreactors resulted in 2.2 higher yields. Highlighting the role of operating under optimal cell culture conditions to maximize the number of EVs secreted per cell, MSCs cultured at lower glucose concentration favored EV secretion. While offline measurements of metabolites concentration can be performed, in this work, Raman spectroscopy was also applied to continuously track glucose levels in stirred‐tank bioreactors, contributing to streamline the selection of optimal EV collection timepoints. Importantly, MSC‐derived EVs retained their quality attributes and were able to stimulate angiogenesis in vitro, therefore highlighting their promising therapeutic potential.


  • Three-Dimensional Co-culture of Human Hematopoietic Stem/Progenitor Cells and Mesenchymal Stem/Stromal Cells in a Biomimetic Hematopoietic Niche Microenvironment

    by Marta H. G. Costa, Tiago S. Monteiro, Susana Cardoso, Joaquim M. S. Cabral, Frederico Castelo Ferreira, Cláudia L. da Silva

    The development of cellular therapies to treat hematological malignancies has motivated researchers to investigate ex vivo culture systems capable of expanding the number of hematopoietic stem/progenitor cells (HSPC) before transplantation. The strategies exploited to achieve relevant cell numbers have relied on culture systems that lack biomimetic niche cues thought to be essential to promote HSPC maintenance and proliferation. Although stromal cells adhered to 2-D surfaces can be used to support the expansion of HSPC ex vivo, culture systems aiming to incorporate cell–cell interactions in a more intricate 3-D environment can better contribute to recapitulate the bone marrow (BM) hematopoietic niche in vitro. Herein, we describe the development of a 3-D co-culture system of human umbilical cord blood (UCB)-derived CD34+ cells and BM mesenchymal stem/stromal cell (MSC) spheroids in a microwell-based platform that allows to attain large numbers of spheroids with uniform sizes. Further comparison with a traditional 2-D co-culture system exploiting the supportive features of feeder layers of MSC is provided, while functional in vitro assays to assess the features of HSPC expanded in the 2-D vs. 3-D MSC co-culture systems are suggested.


  • Bioreactors for the Cultivation of Hematopoietic Stem and Progenitor Cells

    by Marta H.G. Costa, Frederico Castelo Ferreira, Joaquim M. S. Cabral, Cláudia Lobato da Silva

    Transplantation of hematopoietic stem and progenitor cells (HSPC) has been used as a therapeutic option to treat several hemato-oncological diseases. To extend the number of patients that could benefit from HSPC-based therapies, robust bioprocesses need to be implemented for HSPC expansion and/or differentiation. In particular, the clinical use of umbilical cord blood (UCB) as a source of HSPC has been hindered by the low cell numbers available for transplantation. The implementation of HSPC-based therapies, namely using UCB cells, will require the development of scalable cultivation platforms. Herein, we review several culture parameters and tailored bioreactor configurations that would contribute towards the establishment of robust and scalable bioprocesses to expand HSPC. As microenvironment cues are critical to determine self-renewal versus differentiation decisions of primitive cells, different cytokine cocktails, oxygen tensions, pH, cell densities, and medium exchange schemes, either supported by stroma-based co-cultures or integrated in liquid suspension systems, could be explored to achieve clinically relevant cell numbers, particularly when aided by automated and closed-system bioreactors. The implementation of bioengineering strategies, combined with an increased knowledge of cellular biology principles, will enhance the quality and safety of HSPC-based products in a cost-effective manner, accelerating the clinical development of these cell-based therapies.

  • Hematopoietic Niche – Exploring Biomimetic Cues to Improve the Functionality of Hematopoietic Stem/Progenitor Cells

    by Marta H. G. Costa, António M. de Soure, Joaquim M. S. Cabral, Frederico Castelo Ferreira, Cláudia L. da Silva

    The adult bone marrow (BM) niche is a complex entity where a homeostatic hematopoietic system is maintained through a dynamic crosstalk between different cellular and non‐cellular players. Signaling mechanisms triggered by cell‐cell, cell‐extracellular matrix (ECM), cell‐cytokine interactions, and local microenvironment parameters are involved in controlling quiescence, self‐renewal, differentiation, and migration of hematopoietic stem/progenitor cells (HSPC). A promising strategy to more efficiently expand HSPC numbers and tune their properties ex vivo is to mimic the hematopoietic niche through integration of adjuvant stromal cells, soluble cues, and/or biomaterial‐based approaches in HSPC culture systems. Particularly, mesenchymal stem/stromal cells (MSC), through their paracrine activity or direct contact with HSPC, are thought to be a relevant niche player, positioning HSPC‐MSC co‐culture as a valuable platform to support the ex vivo expansion of hematopoietic progenitors. To improve the clinical outcome of hematopoietic cell transplantation (HCT), namely when the available HSPC are present in a limited number such is the case of HSPC collected from umbilical cord blood (UCB), ex vivo expansion of HSPC is required without eliminating the long‐term repopulating capacity of more primitive HSC. Here, we will focus on depicting the characteristics of co‐culture systems, as well as other bioengineering approaches to improve the functionality of HSPC ex vivo.


  • Tridimensional configurations of human mesenchymal stem/stromal cells to enhance cell paracrine potential towards wound healing processes

    by Marta H.G. Costa, Todd C. McDevitt, Joaquim M.S. Cabral, Cláudia L. da Silva, Frederico Castelo Ferreira